Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research

Expands Champions’ product line in unique PDX models

HACKENSACK, NJ – February 16, 2017 – Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the addition of new cohorts of PDX models to their existing TumorBank.

These new models will expand Champions’ product line in hepatocellular cancer, breast cancer, castrate resistant prostate cancer, head and neck cancer, AML, and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) PDX models. These clinically relevant models will be made available to support oncology drug development programs and translational research for industry and academic customers. The addition of these models, with full clinical annotation, increases the Champions TumorBank to greater than 900 clinically relevant patient-derived xenograft models.

“Champions continues to invest in building new models that reflect the evolving standard of care to provide robust model cohorts for pre-clinical research and clinical trial simulation. Champions Medical Affairs and Clinical Operations infrastructure, designed to facilitate research collaborations, allows not only for new PDX model building but also supports building models co-clinically to maximize translational learning from early phase clinical trials,” Dr. Angela Davies, Chief Medical Officer stated.

Ronnie Morris, MD, CEO added, “By making these models commercially available for translational studies at Champions, researchers and pharmaceutical companies will now have access to exclusive animal models integral to drug development research that have been generally inaccessible in the past. In keeping with our core goals of growing the depth and breadth of our TumorBank to accelerate revenue growth, Champions continues to expand its relevant TumorBank, having added over 160 new and unique models in the past 6 months.These new models in addition to our large existing TumorBank continue to be a valuable and cost effective tool for the pharmaceutical industry in their pre-clinical and clinical drug development research. “

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company’s TumorGraft® technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Champions TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for pharmaceutical and biotechnology companies seeking personalized approaches to drug development that can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business, in which results help guide the development of personalized treatment plans for individual patients.